Thaçi D, Körber A, von Kiedrowski R, et al. - In The PROSPECT study (an ongoing 24-week, single-cohort, non-interventional study), experts evaluate former and concomitant psoriasis treatments and transition periods in moderate-to-severe psoriasis patients (n = 1,988) who were receiving secukinumab. Nearly 90.9% of patients had previous systemic treatment. In 44.3% of patients, concomitant treatment was reported. The median duration of the transition period from previous topical, conventional systemic and biologic treatments was 14.0, 30.0 and 44.5 days, respectively. At Week 24, PASI75/90/100 was attained by 86.1%, 68.5% and 39.7% of patients who began secukinumab treatment at baseline. No unexpected safety signals were noted. Thus, the PROSPECT gives a large prospective real-world analysis of secukinumab treatment and involves former and concomitant use of psoriasis treatments in individuals receiving secukinumab in a real-world setting. Moreover, to those observed in the phase 2/3 secukinumab clinical trial programme, secukinumab efficiency and safety were similar.